Form 4: NEOGENOMICS Director Felicia Williams Reports Significant Equity Grants and RSU Vesting

Felicia Williams, a Director at NEOGENOMICS INC, reported the vesting of 7,160 restricted stock units and the acquisition of new stock options and restricted stock units on June 1, 2025.

Summary

• Felicia Williams, a Director of NEOGENOMICS INC (NEO), reported changes in her beneficial ownership of company securities through a Form 4 filing.
• On June 1, 2025, 7,160 Restricted Stock Units (RSUs) vested, converting into 7,160 shares of common stock. These RSUs were previously reported.
• She also acquired 16,107 new stock options with an exercise price of $7.28 per share, which become exercisable on June 1, 2026, and expire on June 1, 2035.
• Additionally, Ms. Williams acquired 23,077 new Restricted Stock Units, which become exercisable on June 1, 2026.
• Following these transactions, Ms. Williams directly owns 7,160 shares of common stock, 16,107 new stock options, 23,077 new restricted stock units, and continues to hold 5,430 existing stock options with an exercise price of $13.59.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects ongoing equity compensation for a director, which is a standard practice to align management interests with shareholders. The vesting of RSUs indicates prior performance conditions were met, and new grants suggest continued commitment and incentive for future performance. There are no sales of shares, only acquisitions and vesting.

Positives

• The vesting of 7,160 Restricted Stock Units indicates a successful completion of performance or time-based conditions for the director.
• The grant of new stock options (16,107 units) and Restricted Stock Units (23,077 units) aligns the director's interests with long-term shareholder value creation, incentivizing future performance.

Future Outlook

NA

Industry Context

This Form 4 filing details routine equity compensation and vesting for a director at NEOGENOMICS INC, a company operating in the diagnostics and oncology testing industry. Such grants are common practice across industries to incentivize and retain key personnel, aligning their interests with long-term company performance.

Related Party Transactions

• The reported transactions are related party transactions as they involve equity compensation granted by NEOGENOMICS INC to its Director, Felicia Williams.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging long-term value creation. The vesting of RSUs increases the director's direct ownership.
• Employees: While not directly impacting all employees, these compensation structures are typical for executive and director roles and reflect standard corporate compensation practices.

Next Steps

• Monitoring the vesting of the newly granted Restricted Stock Units and the exercisability of the new stock options on June 1, 2026.
• Observing any future transactions by Felicia Williams as required by Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Recommendation

Keywords

NEOGENOMICS, NEO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU Vesting, Equity Compensation, Director Ownership, Beneficial Ownership